Launched in 2020 with a mission to make medicines affordable in India, Zeelab Pharmacy founder Rohit Mukul built a ₹200 crore business by re-engineering the pharma supply chain for cost efficiency and consumer benefit.
- Zeelab cuts intermediaries to slash medicine costs drastically
- Shifted from franchising to company-owned stores for better control
- Aims to double revenue to ₹200 Cr in fiscal year 2027
What happened
Founded in April 2020, Zeelab Pharmacy initiated a bold approach to reduce the inflated costs of medicines in India. The founder, Rohit Mukul, identified excessive middlemen in the supply chain as the core reason for steep price hikes, with costs sometimes increasing tenfold before reaching consumers. Zeelab commenced operations in Delhi and gradually expanded to over 300 stores, now processing around 10,000 orders daily both online and offline.
Originally experimenting with franchising to scale its footprint, Zeelab pivoted to a company-owned store model after discovering franchisees struggled to maintain proper inventory levels. This realignment allowed Zeelab to retain tighter control over stock availability and pricing, reinforcing its core value proposition of affordability and reliable access.
Why it matters
Pharmaceutical products differ from other retail items because patients cannot forgo essential medicines based on cost, making pricing transparency and affordability critical public health issues in India. Zeelab’s approach challenges the market norm where consumers often unknowingly pay significantly inflated prices, sometimes six times higher than necessary, for common medicines.
By embedding affordability as the brand’s identity rather than a temporary discount, Zeelab aims to establish trust and long-term loyalty among consumers who recognize the genuine value in its pricing. This business model also exemplifies how structural improvements in supply chain management can achieve scale without sacrificing cost leadership.
What to watch next
Zeelab targets to nearly double its revenue from approximately ₹110 crore in fiscal 2026 to ₹200 crore in fiscal 2027. The company’s ability to maintain its price advantage and sustain consumer trust will be critical as it scales further and faces competitive pressures from both local and national pharmacy chains.
Continued innovation in integrating offline stores with a digital ordering platform will be vital for Zeelab to enhance customer experience and operational efficiency. Additionally, how Zeelab balances expansion while preserving the affordability promise will provide insight into the viability of disruptive models in India’s highly fragmented pharmaceutical retail sector.